Switch theme
Sign up to access all valuation multiples
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
2016
342
LTM Revenue $244M
LTM EBITDA -$100M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Arcutis Biotherapeutics has a last 12-month revenue (LTM) of $244M and a last 12-month EBITDA of -$100M.
In the most recent fiscal year, Arcutis Biotherapeutics achieved revenue of $197M and an EBITDA of -$110M.
Arcutis Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arcutis Biotherapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $244M | XXX | $197M | XXX | XXX | XXX |
| Gross Profit | $218M | XXX | $177M | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | -$100M | XXX | -$110M | XXX | XXX | XXX |
| EBITDA Margin | -41% | XXX | -56% | XXX | XXX | XXX |
| EBIT | -$102M | XXX | -$128M | XXX | XXX | XXX |
| EBIT Margin | -42% | XXX | -65% | XXX | XXX | XXX |
| Net Profit | -$111M | XXX | -$140M | XXX | XXX | XXX |
| Net Margin | -46% | XXX | -71% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $35.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Arcutis Biotherapeutics's stock price is $13.
Arcutis Biotherapeutics has current market cap of $1.6B, and EV of $1.5B.
See Arcutis Biotherapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $1.6B | XXX | XXX | XXX | XXX | $-0.91 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Arcutis Biotherapeutics has market cap of $1.6B and EV of $1.5B.
Arcutis Biotherapeutics's trades at 7.5x EV/Revenue multiple, and -13.4x EV/EBITDA.
Equity research analysts estimate Arcutis Biotherapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arcutis Biotherapeutics has a P/E ratio of -13.9x.
See valuation multiples for Arcutis Biotherapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 7.5x | XXX | XXX | XXX |
| EV/EBITDA | -14.6x | XXX | -13.4x | XXX | XXX | XXX |
| EV/EBIT | -14.4x | XXX | -11.4x | XXX | XXX | XXX |
| EV/Gross Profit | 6.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -13.9x | XXX | -11.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -12.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArcutis Biotherapeutics's last 12 month revenue growth is 47%
Arcutis Biotherapeutics's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.9M for the same period.
Arcutis Biotherapeutics's rule of 40 is -335% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arcutis Biotherapeutics's rule of X is 77% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Arcutis Biotherapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 47% | XXX | 48% | XXX | XXX | XXX |
| EBITDA Margin | -41% | XXX | -56% | XXX | XXX | XXX |
| EBITDA Growth | -54% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -335% | XXX | -8% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 77% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 156% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arcutis Biotherapeutics acquired XXX companies to date.
Last acquisition by Arcutis Biotherapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Arcutis Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Arcutis Biotherapeutics founded? | Arcutis Biotherapeutics was founded in 2016. |
| Where is Arcutis Biotherapeutics headquartered? | Arcutis Biotherapeutics is headquartered in United States of America. |
| How many employees does Arcutis Biotherapeutics have? | As of today, Arcutis Biotherapeutics has 342 employees. |
| Who is the CEO of Arcutis Biotherapeutics? | Arcutis Biotherapeutics's CEO is Mr. Todd Franklin Watanabe. |
| Is Arcutis Biotherapeutics publicy listed? | Yes, Arcutis Biotherapeutics is a public company listed on NAS. |
| What is the stock symbol of Arcutis Biotherapeutics? | Arcutis Biotherapeutics trades under ARQT ticker. |
| When did Arcutis Biotherapeutics go public? | Arcutis Biotherapeutics went public in 2020. |
| Who are competitors of Arcutis Biotherapeutics? | Similar companies to Arcutis Biotherapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Arcutis Biotherapeutics? | Arcutis Biotherapeutics's current market cap is $1.6B |
| What is the current revenue of Arcutis Biotherapeutics? | Arcutis Biotherapeutics's last 12 months revenue is $244M. |
| What is the current revenue growth of Arcutis Biotherapeutics? | Arcutis Biotherapeutics revenue growth (NTM/LTM) is 47%. |
| What is the current EV/Revenue multiple of Arcutis Biotherapeutics? | Current revenue multiple of Arcutis Biotherapeutics is 6.0x. |
| Is Arcutis Biotherapeutics profitable? | Yes, Arcutis Biotherapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Arcutis Biotherapeutics? | Arcutis Biotherapeutics's last 12 months EBITDA is -$100M. |
| What is Arcutis Biotherapeutics's EBITDA margin? | Arcutis Biotherapeutics's last 12 months EBITDA margin is -41%. |
| What is the current EV/EBITDA multiple of Arcutis Biotherapeutics? | Current EBITDA multiple of Arcutis Biotherapeutics is -14.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
